A QUT researcher’s identification of saliva as an early detection liquid biopsy for oral and throat cancer has been realised by the development and commercialisation of a diagnostic device by US-based biotech company Viome.
Viome’s early detection device has been designated a Breakthrough Device by The Food and Drug Administration (FDA) in the US.
QUT Associate Professor Chamindie Punyadeera (pictured) has spent a decade researching the possibility of saliva being the optimum diagnostic liquid for the early detection of oral and throat cancer. More info.